Growth Hormone Deficiency and Treatment in Childhood Cancer Survivors

Netanya I. Pollock, Laurie E. Cohen

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Growth hormone (GH) deficiency is a common pituitary hormone deficiency in childhood cancer survivors (CCS). The identification, diagnosis, and treatment of those individuals at risk are important in order to minimize associated morbidities that can be ameliorated by treatment with recombinant human GH therapy. However, GH and insulin-like growth factor-I have been implicated in tumorigenesis, so there has been concern over the use of GH therapy in patients with a history of malignancy. Reassuringly, GH therapy has not been shown to increase risk of tumor recurrence. These patients have an increased risk for development of meningiomas, but this may be related to their history of cranial irradiation rather than to GH therapy. In this review, we detail the CCS who are at risk for GHD and the existing evidence on the safety profile of GH therapy in this patient population.

Original languageEnglish (US)
Article number745932
JournalFrontiers in Endocrinology
StatePublished - Oct 22 2021
Externally publishedYes


  • brain tumors
  • childhood cancer survivors (CCS)
  • growth hormone deficiency
  • growth hormone treatment
  • secondary neoplasm
  • tumor recurrence

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Growth Hormone Deficiency and Treatment in Childhood Cancer Survivors'. Together they form a unique fingerprint.

Cite this